Nature Reviews Drug Discovery

Betting on β-catenin inhibitors in oncology

Asher Mullard Jan 01, 2026 pp. 3-7 10.1038/d41573-025-00206-8

Calico, Alphabet’s anti-ageing play, goes it alone

Asher Mullard Jan 01, 2026 pp. 14-15 10.1038/d41573-025-00205-9

Top product forecasts for 2026

Paul Verdin Jan 01, 2026 pp. 10-10 10.1038/d41573-025-00203-x

Upcoming FDA approval decisions in Q1 2026

Andrew Shui-Jezierski Jan 01, 2026 pp. 11-11 10.1038/d41573-025-00204-w

First-in-class APRIL inhibitor secures approval for rare kidney disease

Asher Mullard Jan 01, 2026 pp. 9-9 10.1038/d41573-025-00202-y

Pathway-selective 5-HT1AR agonist speeds up antidepressant effect

M. Teresa Villanueva Jan 01, 2026 pp. 20-20 10.1038/d41573-025-00201-z

Stimulating medicines repurposing in the EU: a pilot project

Christelle Bouygues, Anna Tavridou, Ralf Herold et al. Jan 01, 2026 pp. 12-13 10.1038/d41573-025-00198-5

Omics with active learning optimizes phenotypic screens

Alex Eccleston Jan 01, 2026 pp. 19-19 10.1038/d41573-025-00200-0

Novel antimalarial passes key phase III test

Asher Mullard Jan 01, 2026 pp. 8-8 10.1038/d41573-025-00193-w

Designing G-protein-selective allosteric modulators

Sarah Crunkhorn Jan 01, 2026 pp. 21-21 10.1038/d41573-025-00197-6

Enhancing RNA stability

Sarah Crunkhorn Jan 01, 2026 pp. 21-21 10.1038/d41573-025-00195-8

A broad-spectrum snakebite antivenom

Sarah Crunkhorn Jan 01, 2026 pp. 21-21 10.1038/d41573-025-00194-9

Repairing spinal cord damage

Sarah Crunkhorn Jan 01, 2026 pp. 21-21 10.1038/d41573-025-00196-7

Halda secures biggest induced-proximity deal yet, with J&J’s US$3 billion buy out

Asher Mullard Jan 01, 2026 pp. 9-9 10.1038/d41573-025-00190-z

Magnetic microrobots provide targeted drug delivery

Katie Kingwell Jan 01, 2026 pp. 19-19 10.1038/d41573-025-00192-x

Accelerating progress in immune cell therapy for solid tumours

Adrian Bot, Mark Dudley, Daniel Shelley et al. Jan 01, 2026 pp. 1-2 10.1038/d41573-025-00191-y

Triggering ferroptosis to tackle cancer

Sarah Crunkhorn Jan 01, 2026 pp. 18-18 10.1038/d41573-025-00189-6

Trends in gene therapy delivery technologies

Emily Capra, Ling Liu, Alberto Loche et al. Jan 01, 2026 pp. 16-17 10.1038/d41573-025-00171-2

RNA modification systems as therapeutic targets

Linda Zhang, Jiangbo Wei, Zhongyu Zou et al. Jan 01, 2026 pp. 59-78 10.1038/s41573-025-01280-8

Microsystem technologies for accelerating the discovery and translation of immunotherapies

Zongjie Wang, Claire Liu, Kangfu Chen et al. Jan 01, 2026 pp. 39-58 10.1038/s41573-025-01268-4

Synthetic lethality in cancer drug discovery: challenges and opportunities

Emanuel Gonçalves, Colm J. Ryan, David J. Adams Jan 01, 2026 pp. 22-38 10.1038/s41573-025-01273-7